HIV resistance to lenacapavir weakens the virus's ability to replicate

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with drug-resistant infections in 2022. While there is still no vaccine for the virus, the twice-yearly injectable is “the next…

Continue Reading

News Source: medicalxpress.com